New hope for rare salivary gland cancer: targeted drug combo enters trial
Disease control
Recruiting now
This study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. About 90 adults will receive treatment every three weeks for up to two years. The goal is to see if the drugs shrink tumors and are safe…
Phase: PHASE2 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC